• Home
  • NEW DAY MEDICINE
  • 4 (78) 2025
  • 61 -4 (78) 2025 - I.R. Agababyan, N.G. Nizamova - THE DYNAMICS OF THE MICROCIRCULATORY SYSTEM IN DIFFERENT PHENOTYPES OF CHRONIC HEART FAILURE WITH BASIC THERAPY

61 -4 (78) 2025 - I.R. Agababyan, N.G. Nizamova - THE DYNAMICS OF THE MICROCIRCULATORY SYSTEM IN DIFFERENT PHENOTYPES OF CHRONIC HEART FAILURE WITH BASIC THERAPY

THE DYNAMICS OF THE MICROCIRCULATORY SYSTEM IN DIFFERENT PHENOTYPES OF CHRONIC HEART FAILURE WITH BASIC THERAPY

I.R. Agababyan - Samarkand State Medical University

N.G. Nizamova - Samarkand State Medical University

Resume

Chronic heart failure (CHF) is a multifaceted syndrome characterised by the heart's inability to pump sufficient blood to meet metabolic demands, leading to significant morbidity and mortality worldwide. Chronic heart failure (CHF) is a complex and progressive syndrome marked by the heart’s inability to supply blood to meet the body's metabolic demands adequately. As a significant global health challenge, CHF affects millions of individuals worldwide, with its prevalence rising due to aging populations and increasing cardiovascular risk factors such as hypertension, diabetes mellitus, and obesity. Despite advances in diagnosis and treatment, CHF remains associated with significant morbidity, frequent hospitalisations, and a high economic burden on healthcare systems. One of the most critical yet often overlooked aspects of CHF pathophysiology is microcirculatory dysfunction, which plays a pivotal role in disease progression and therapeutic response. This review provides a comprehensive overview of the pathophysiology, various phenotypes of CHF, and a wide array of treatment options, emphasising the emerging therapeutic potential of sacubitril/valsartan. Additionally, it examines the effects, complications, and clinical evidence surrounding these treatment modalities, aiming to guide future research and clinical practice.

Key words: Chronic heart failure, hypertension, microcirculatory dysfunction, progression, sacubitril/valsartan

First page

372

Last page

383

For citation:I.R. Agababyan, N.G. Nizamova - THE DYNAMICS OF THE MICROCIRCULATORY SYSTEM IN DIFFERENT PHENOTYPES OF CHRONIC HEART FAILURE WITH BASIC THERAPY//New Day in Medicine 4(78)2025 372-383 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. Adams, J. R., et al. (2022). Safety and tolerability of Sacubitril/valsartan in chronic heart failure: A clinical evaluation. Journal of Cardiac Failure, 2022;28(4):490-499.
  2. Ahmed, A., et al. (2010). The influence of renal function on clinical outcomes after hospitalisation for heart failure. Journal of Cardiac Failure, 2010;16(1):39-46.
  3. Bellomo, R., et al. (2017). Acute kidney injury: an overview. The Lancet, 2017;389(10084):825-835.
  4. Bennett, J. L., et al. (2021). Myocardial contrast echocardiography for evaluating microvascular function in heart failure. Echocardiography, 2021;38(9):1522-1531.
  5. Black, S. M., et al. (2023). Reducing heart failure hospitalization: A prospective study on Sacubitril/valsartan. Heart and Vessels, 2023;38(1):155-162.
  6. Boegehold, M. A., et al. (2021). Cardiac magnetic resonance imaging in heart failure patients: Reassessing microvascular function. Journal of Cardiac Failure, 2021;27(3):322-330.
  7. Böhm, M., et al. (2020). The role of endothelial dysfunction in chronic heart failure: Implications for therapy. European Heart Journal, 2020;41(23):2158-2169.
  8. Borlaug, B. A. (2021). The pathophysiology of heart failure with preserved ejection fraction. Nature Reviews Cardiology 2021;18(10):702-717.
  9. Borlaug, B. A., Paulus, W. J. (2011). Heart failure with preserved ejection fraction: a different disease. Clinical Chemistry, 2011;57(3):375-387.
  10. Borlaug B. A., et al. (2020). Pharmacotherapy for heart failure with preserved ejection fraction: Emerging treatments and clinical trial results. Circulation: Heart Failure, 2020;13(2):e007352.
  11. Bristol, L. A., et al. (2019). Prognosis of patients with end-stage heart failure: A multi-dimensional approach." Clinical Cardiology 2019;42(2):178-185.
  12. Bucher, H. C., et al. (2018). "Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Events: A Meta-Analysis." Journal of the American College of Cardiology, 2018;71(3):276-286.
  13. Celano, C. M., et al. (2018). Depression and anxiety in patients with heart failure: a clinical review. Journal of Cardiovascular Nursing, 2018;33(3):239-245.
  14. Corrà, U., et al. (2017). "Exercise Training in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis." European Journal of Preventive Cardiology, 2017;4(10):1080-1093.
  15. Deng, Y., et al. (2021). Stem cell therapy for heart failure: Current status and future directions. Heart Failure Reviews, 2021;26(4):883-898.
  16. Ehrlich, T. J., et al. (2020). Clinical assessment of heart failure. Heart Failure Clinics, 2020;16(4):579-595.
  17. Ghadge, A., et al. (2022). Optimising diuretic therapy in heart failure: a practical approach. European Journal of Heart Failure, 2022;24(7):1275-1284.
  18. Gheorghiade, M., et al. (2013). Heart failure: a growing global epidemic. European Journal of Heart Failure, 2013;15(3):221-226.
  19. Green, T. A., et al. (2022). Meta-analysis of Sacubitril/valsartan's safety profile in heart failure patients. European Journal of Heart Failure, 2022;24(5):789-798.
  20. Heidenreich, P. A., et al. (2019). Forecasting the Impact of Heart Failure in the United States. Circulation: Heart Failure, 2019;12(6):e00549.

    file

    download